Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
Condition(s):Glanzmann ThrombastheniaLast Updated:January 31, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Glanzmann ThrombastheniaLast Updated:January 31, 2024Completed
Condition(s):Glanzmann ThrombastheniaLast Updated:March 7, 2024Completed
Condition(s):Glanzmann ThrombastheniaLast Updated:January 18, 2024Recruiting
Condition(s):Glanzmann ThrombastheniaLast Updated:March 13, 2024Completed
Condition(s):Glanzmann ThrombastheniaLast Updated:February 28, 2024Not yet recruiting
Condition(s):Congenital Bleeding Disorder; Glanzmann’s DiseaseLast Updated:December 23, 2014Completed
Condition(s):Congenital Bleeding Disorder; Glanzmann’s DiseaseLast Updated:July 11, 2017Completed
Condition(s):Glanzmann ThrombastheniaLast Updated:July 6, 2023Recruiting
Condition(s):Von Willebrand Diseases; Glanzmann ThrombastheniaLast Updated:September 7, 2023Recruiting
Condition(s):Ischemic Heart Disease; Angina Pectoris; Coronary Artery Disease; Coronary Artery Occlusion; Myocardial IschemiaLast Updated:August 1, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.